The Clinical Trials Information Centre aims to give you information about what clinical trials are taking place that you may be eligible for. The search function below allows you to search by your location, your treatment stage and the stage of the trial. If you find a trial you think you may be eligible for, we suggest you print the information to take along to your next appointment with your clinical team as you will not be able to join the trial without the support of your clinical team.

In addition to the larger trials taking place in centres across the UK, there are sometimes phase I trials which have an even stricter entry criteria. We have not listed all of these but have instead listed where the phase I centres are so that you can ask your clinical team to contact them to find out if there’s any trials you may be eligible for.

This site will be updated regularly as trials are opening and closing in different locations all the time. Whilst we endeavour to keep it as up to date as we can, please always check with your clinical team about the availability of a trial in your area.

If you have any queries about the clinical trials information centre, you can call the Target Ovarian Cancer support line on 020 7923 5475 or email

Miles of

Results list

This trial is looking at whether the additional drug treatment of avelumab alongside platinum based chemotherapy improves progression free survival (the length of time during and after treatment that a woman lives with the disease but it does not get worse) in women with stage III / IV disease at diagnosis. It is a three arm trial:
The aim of this study is to determine whether elemental diet (a type of drink that contains an elemental protein source known as amino acids) can be tolerated by patients with inoperable bowel blockage who can no longer eat and are only able to swallow small amount of fluid. The objective is to find out whether elemental diet can be used as an acceptable nutrition at home and whether it improves the quality of life.
Clear cell cancer is a rare type of cancer. If it starts in the ovary or the lining of the womb (endometrium), doctors often treat it with surgery followed by chemotherapy. But sometimes the cancer can continue to grow or come back after treatment. In this situation chemotherapy is not always helpful and so researchers are looking for new treatments. In this trial they are looking at a drug called nintedanib.
Surgery is the usual treatment for ovarian cancer. A CT scan is used to check where the cancer is in the body and helps doctors to know if surgery would be a suitable treatment choice.  However, sometimes the CT scan can’t:
The study will assess the efficacy of niraparib as maintenance treatment. This study is a randomized study in patients with stage III or IV ovarian cancer. It is double-blind so neither the doctor nor the patient will know if they are on Niraparib or the placebo.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer
Women will be randomised into two groups:                   Group B1 Women in this group will receive 18 weeks of: Carboplatin once every three weeks Paclitaxel once every three weeks Bevacizumab once every three weeks followed by bevacizumab continuing alone for approximately 11 months Group B3 Women in this group will receive 18 weeks of:
To fully understand the benefits of a PARP inhibitor versus standard chemotherapy for BRCA positive women who have had two previous treatments. The trial is a three arm trial, women will be randomised to:
ICON9 is a randomised study and patients will be randomly allocated to receive one or both of the anti-cancer drugs on completion of their chemotherapy (called maintenance treatment).  Patients will be in the study for up to 6 years and will continue taking the study tablets until their study doctor thinks they are no longer helping to control the disease. Study tablets may also be discontinued by the study doctor if patients experience side effects that have a negative impact on their quality of life. 
PARP inhibitors, such as olaparib, significantly improve progression free survival (PFS) in participants with recurrent, platinum-sensitive high-grade serous/endometrioid ovarian cancer (HGS/EOC), who have a mutation in BRCA 1 or 2 genes.  The investigators will test the feasibility of administering a second course of olaparib in participants who have recurrent platinum-sensitive HGS/EOC.  
This is a three arm trial, both phase I and phase II dependent upon the arm that the woman is randomised to: Phase Ib: APR-246 + Carboplatin/Caelyx. Phase II: Arm A. APR-246 + Carboplatin/Caelyx Phase II: Arm B. Carboplatin/Caelyx    
Women will be randomised to one of three treatment groups:  Paclitaxel – weekly intravenously  Olaparib – taken orally, twice daily  Olaparib and cediranib – taken orally, twice daily and once daily respectively 
The aims of the trial are to: Help diagnose ovarian cancer earlier when treatment is likely to work better Help identify which women need further investigations for possible ovarian cancer and reduce unnecessary tests, hospital visits and distress in women who do not have ovarian cancer The researchers hope that the information they collect will help to improve diagnosis for women with ovarian cancer in the future.
The study aims to recruit approximately 275 patients   Patients will receive olaparib as an oral medication at a dose of 400mg twice a day.
To compare the overall survival (OS) after primary debulking surgery (PDS) versus interval debulking surgery (IDS) following neoadjuvant chemotherapy (NACT) in patients with FIGO (2014) stage IIIB-IVB ovarian, tubal, and peritoneal carcinoma.